The PennZone

  • Home
  • Business
  • Non-profit
  • Health
  • Technology
  • Construction
  • Travel
  • Real Estate
  • Entertainment

Rimsys’ 2023 Regulatory Performance Report Finds a Growing Emphasis on Digital Transformation in MedTech Regulatory Affairs
The PennZone/10219057

Trending...
  • "They Said It Was Impossible": This Bottle Turns Any Freshwater Source Into Ice-Cold, Purified Drinking Water in Seconds
  • TL International Group Becomes First Global Operator to Fully Migrate to Pulsant's Dedicated Car Rental Cloud
  • Excel Signworks Introduces Custom Lobby Signs to Help Pittsburgh Businesses Elevate First Impressions in 2026
PITTSBURGH--(BUSINESS WIRE)--Rimsys, the leading provider of Regulatory Information Management (RIM) software for the medtech industry, today announced the release of the 2023 Regulatory Performance Report, a new study that tracks trends in regulatory priorities, processes, and performance within medtech companies. The report is based on a survey of 200 regulatory professionals and executives across North America and Europe.

The report explores how regulatory affairs teams are staffed, their workload, average times to complete regulatory projects, where they experience compliance issues, and the growing trend of accelerating digital transformation within the industry.

"The need for this report was driven by conversations with several of our customers," said James Gianoutsos, Founder and CEO of Rimsys. "Regulatory leaders don't have clear benchmarks to measure the performance of their teams. They're looking at digital transformation initiatives to improve the efficiency and effectiveness of their teams and want to understand what's possible, what really good execution looks like."

Key findings include:

Regulatory teams are lightly staffed compared to their workload.

A quarter of large medtech companies have 15 or fewer regulatory employees. These small teams complete over 100 renewals or license updates each year. Only 13% of companies make resourcing decisions based on anticipated workload, leaving any gaps to be filled with external consultants. Today, 90% of companies rely on consultants to complete regulatory projects.

Process failures are common.

Regulatory leaders self-assess the performance of their teams highly. A majority believe they outperform other regulatory affairs teams in similar companies in both project planning and execution. Yet over 60% reported a major non-compliance issue in that past year, and 24% had to withdraw products from a country or region due to non-compliance.

More on The PennZone
  • CCHR: Decades of Warnings, Persistent Inaction; Studies Raise New Alarms on Psychiatric Drug Safety
  • PRÝNCESS Builds Anticipation With "My Nerves" — A Girls-Girl Anthem
  • Arbutus Medical Raises C$9.3M to Accelerate Growth of Surgical Workflow Solutions Outside the OR
  • From Sleepless Nights to Sold-Out Drops: Catch Phrase Poet's First Year Redefining Motivational Urban Apparel
  • Now Live on Kickstarter: The Bottle That Chills and Purifies Any Freshwater — and Donates One for Every 10 Backers

Digital transformation makes a measurable impact on productivity.

Companies are investing in process improvement, both by increasing staffing and growing technology budgets. They are moving away from generic productivity tools to more specialized solutions designed for regulatory processes. Companies that have implemented regulatory information management and regulatory intelligence systems report very high productivity gains and they complete regulatory projects more quickly.

Rimsys and PA Consulting, a global innovation and transformation consultancy, in conjunction with the Regulatory Affairs Professionals Society, will be presenting and discussing the survey findings in an interactive webinar on February 23, 2023. To attend, register here: https://bit.ly/performance-study-webinar.

"A major trend we are tracking this year is focused on Medtech's engagement with regulatory bodies against a backdrop of new requirements for advanced technologies such as AI, and evolving legislation such as the MDR and IVDR transition in Europe. This has forced organizations to re-evaluate old processes and adopt new tools," said Marck Aghnatios, MedTech Expert at PA Consulting. "The impact of this change will be largely absorbed by the regulatory affairs function – which is accurately reflected Rimsys' study findings. The industry imperative for medtech leaders will be to digitize their business functions – starting with regulatory."

Methodology

More on The PennZone
  • How Specialized Game Development Services Are Powering the Next Wave of Interactive Entertainment
  • Brain Drain Unlimited Strengthens Legal Advocacy with Advanced Training from Villanova University
  • Don't Settle for a Lawyer Who Just Speaks Spanish. Demand One Who Understands Your Story
  • Dan Williams Promoted to Century Fasteners Corp. – General Manager, Operations
  • Ski Johnson Inks Strategic Deals with Three Major Food Chain Brands

Rimsys worked with a third-party market research firm to field and administer the survey in July 2022. Survey respondents included 200 regulatory professionals at medtech (medical device, in vitro diagnostic, and software as a medical device) companies headquartered in the United States, Canada, and the European Union. Companies were evenly sampled across all sizes, from $10 million to more than $1 billion in revenue.

To download the full Regulatory Performance report, please visit: https://www.rimsys.io/regulatory-performance-report.

About Rimsys

Rimsys is improving global health by accelerating delivery and increasing availability of life-changing medical technologies. Rimsys Regulatory Information Management (RIM) software digitizes and automates regulatory activities, helping medtech regulatory affairs teams to plan more effectively, execute more quickly, and confidently ensure global regulatory compliance. Unlike complex, color-coded spreadsheets, or expensive external consultants, Rimsys centralizes all regulatory information, automates submission processes, and provides detailed visibility into product registrations, expirations, relevant standards, and global regulations. Traditional approaches to regulatory affairs can't keep pace with the growing complexity of the global landscape, and overburdened teams face increasing compliance risks. Rimsys is designed around medtech regulations and workflows and supports a full breadth of regulatory activities including registrations, submissions, UDI, essential principles, standards management, and regulatory intelligence in a single, integrated platform. Leading global medtech companies including Johnson & Johnson, Siemens Healthineers, and Omron rely on Rimsys to better manage regulatory projects and resources, get new products to market more quickly, and reduce revenue risk of non-compliance, product recalls, and unexpected expirations. For more information, visit www.rimsys.io.​

Contacts

Michael Peach
(855) 846-7269
michael.peach@rimsys.io
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • "They Said It Was Impossible": This Bottle Turns Any Freshwater Source Into Ice-Cold, Purified Drinking Water in Seconds
  • Patron Saints Of Music Names Allie Moskovits Head Of Sync & Business Development
  • Dave Aronberg Named 2026 John C. Randolph Award Recipient by Palm Beach Fellowship of Christians & Jews
  • General Relativity Challenged by New Tension Discovered in Dark Siren Cosmology
  • Burkentine Real Estate Group to Bring A New Community to Millersville, Pennsylvania
  • Unseasonable Warmth Triggers Early Pest Season Along I-5 Corridor
  • VIP Vacations Named Winner in 2026 WeddingWire Couples' Choice Awards®
  • Colonial Nissan Champions Community Service and Trust Across the Greater Philadelphia Region
  • Bug Busters Expands Service Footprint With New Carrollton, Georgia Branch
  • Why KULR Could Be a Quiet Enabler of Space-Based Solar Power (SBSP) Over The Long Term: KULR Technology Group, Inc. (NY SE American: KULR)
  • Why Finland Had No Choice But to Legalize Online Gambling
  • High-Margin Energy & Digital Infrastructure Platform Created after Merger with Established BlockFuel Energy, Innovation Beverage Group (NAS DAQ: IBG)
  • iFLO Pro Launches Its Groundbreaking iFLO Pro Mini At The 2026 AHR Expo In Las Vegas
  • TL International Group Becomes First Global Operator to Fully Migrate to Pulsant's Dedicated Car Rental Cloud
  • Diveroli Investment Group Files 13D in PetMed Express, Highlights Strategic Value, Asset Floor, and Multiple Takeover Pathways
  • Excel Signworks Introduces Custom Lobby Signs to Help Pittsburgh Businesses Elevate First Impressions in 2026
  • Deep Learning Robotics (DLRob) Announces Pre-Launch of Zero-Teach and Teach-by-Demonstration Technology for Kitting Applications
  • The Quasar Dipole Phenomenon is likely just a complex systematics artifact
  • The Rise of Comprehensive Home Water Treatment Systems
  • Yazaki Innovations to Introduce First-Ever Prefabricated Home Wiring System to U.S. Residential Market in 2026

Popular on PennZone

  • Mark Schork Selected As 'Board Observer' By Philadelphia Bar Foundation - 168
  • Michael Judkins Releases New Poetry Book, Deeper Than You Think
  • Steve Everett Jr. Named President of L.T. Hampel Corporation
  • $80 Million Revenue Backlog for AI Cybersecurity Company Building the Future of Integrated Cybersecurity and Public Safety: $CYCU
  • Precision Adult Care Expands 24/7 Adult In-Home Care Services to Meet Growing Demand in the Coachella Valley
  • Accountants Near Me Cheyenne Opens U.S. Directory for Accountants, Bookkeepers and Tax Services
  • Boston Industrial Solutions' BPA Certified BX Series Raises the Bar for Pad Printing Inks
  • Boston Industrial Solutions' Natron® 512N Series UV LED Ink Earns CPSIA Certification
  • Why 'Instant-Liquidity' Gaming is Dominating the Nordic Tech Demographic
  • NOW OPEN - New Single Family Home Community in Manalapan

Similar on PennZone

  • FDA Meeting Indicates a pivotal development that could redefine the treatment landscape for suicidal depression via NRx Pharmaceuticals: $NRXP
  • $2.7 Million 2025 Revenue; All Time Record Sales Growth; 6 Profitable Quarters for Homebuilding Industry: Innovative Designs (Stock Symbol: IVDN)
  • How Specialized Game Development Services Are Powering the Next Wave of Interactive Entertainment
  • NIL Club Advances Agent-Free NIL Model as Oversight Intensifies Across College Athletics
  • Slotozilla Reports Strong Q4 Growth and Sigma Rome Success
  • Families Gain Clarity: Postmortem Pathology Expands Private Autopsy Services in St. Louis
  • Amy Turner Receives 2025 ENPY Partnership Builder Award from The Community Foundation
  • Vines of Napa Launches Partnership Program to Bolster Local Tourism and Economic Growth
  • Finland's €1.3 Billion Digital Gambling Market Faces Regulatory Tug-of-War as Player Protection Debate Intensifies
  • Patron Saints Of Music Names Allie Moskovits Head Of Sync & Business Development
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us